Lavaca Capital LLC lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 7.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,395 shares of the biopharmaceutical company’s stock after buying an additional 295 shares during the quarter. Lavaca Capital LLC’s holdings in Bristol-Myers Squibb were worth $238,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in BMY. Northwest Financial Advisors bought a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $27,000. ESL Trust Services LLC bought a new position in Bristol-Myers Squibb during the first quarter worth about $27,000. Accordant Advisory Group Inc acquired a new position in Bristol-Myers Squibb during the first quarter worth approximately $31,000. Pacific Capital Wealth Advisors Inc. bought a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $34,000. Finally, Turtle Creek Wealth Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $40,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.
Bristol-Myers Squibb Price Performance
Shares of NYSE BMY traded down $1.48 during mid-day trading on Monday, reaching $48.97. The company had a trading volume of 22,276,796 shares, compared to its average volume of 15,962,543. The firm has a market cap of $99.27 billion, a price-to-earnings ratio of -15.80, a PEG ratio of 17.25 and a beta of 0.44. The business’s 50-day simple moving average is $41.87 and its 200 day simple moving average is $46.75. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.41. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11.
Bristol-Myers Squibb Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.90%. The ex-dividend date of this dividend is Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is presently -77.42%.
Analyst Ratings Changes
A number of research analysts recently weighed in on BMY shares. Barclays lowered Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and set a $41.00 target price on the stock. in a report on Monday. Wells Fargo & Company increased their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday, April 18th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $45.00 price target on shares of Bristol-Myers Squibb in a research note on Monday, July 22nd. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a report on Tuesday, July 23rd. Finally, StockNews.com raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $55.79.
Get Our Latest Stock Analysis on BMY
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Featured Articles
- Five stocks we like better than Bristol-Myers Squibb
- Why Are These Companies Considered Blue Chips?
- Survey: Top 175 Fittest Retirement Locations in America
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- About the Markup Calculator
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.